載入中
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
收盤時
US$2.78
US$0.00 · 0.00%
盤後
US$2.81
+US$0.03 · +1.08%
10月12日 下午4:25 ET
盤中時間採用ET。市場資料可能有所延遲。
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
日內區間
目前US$2.78
52週區間
目前US$2.78
盤中時間採用ET。市場資料可能有所延遲。
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
日內區間
目前US$2.78
52週區間
目前US$2.78
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$6.00
上漲空間 115.83%報告持有此股票曝險的交易所交易基金。
iShares Russell 2000 ETFIWM544.61萬0.01%787.4億 USD0.19%US$277.88-0.38%
Schwab International Small-Cap Equity ETFSCHC244.54萬0.04%55.33億 USD0.06%US$49.13-0.69%
iShares Russell 2000 Growth ETFIWO207.14萬0.01%139.17億 USD0.24%US$353.71-0.86%
State Street SPDR Portfolio Developed World ex-US ETFSPDW194.86萬0.00%404.62億 USD0.03%US$49.69-0.58%
Vanguard Russell 2000 ETFVTWO108.99萬0.01%180億 USD0.06%US$112.27-0.35%
iShares Micro-Cap ETFIWC70.5萬0.05%13.17億 USD0.60%US$181.66-0.73%
Dimensional - US Small Cap ETFDFAS67.84萬0.00%338.69億 USD0.31%US$78.17-0.23%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM27萬0.23%1.17億 USD0.73%US$15.86-0.50%iShares Russell 2000 ETFIWMSchwab International Small-Cap Equity ETFSCHCiShares Russell 2000 Growth ETFIWOState Street SPDR Portfolio Developed World ex-US ETFSPDWVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCDimensional - US Small Cap ETFDFASEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
